Contacting Citryll as patient or other interested party
Patients contacting us because they are interested in participating in future clinical research at Citryll will need to sign an informed consent form in order for us to keep your contact details and other information provided. This website contains information relating to health, diseases and treatments. This is for information purposes only and is not meant to be a substitute for the advice provided by your own doctor or healthcare professional. You should not use the information contained herein for diagnosing any illness or physical or mental issue. Citryll will not respond to any such request, you should always consult your own doctor or healthcare professional.
Partnering with Citryll
Collaborations are an important element in Citryll’s strategy to bring tACPA to clinical Proof of Concept and ultimately to patients. We are exploring the broader potential for clinical utility of mitigating dysregulated NET activity with academic collaborators and industry partners. Citryll has a proprietary toolbox to study NET biology and protein citrullination and their role in human pathologies. This toolbox enables us together with our academic and industry partners to study the role of NETs in human disease biology on the one hand and the medical utility of tACPA lead compounds on the other hand.
We are keen to explore opportunities to collaborate and partner with companies whose expertise in relevant therapeutic areas and clinical development of therapeutic antibodies will aid us in the development of innovative medicines addressing true medical need.
Part of Citryll’s strategy is to collaborate with academic groups with a keen interest and/or track-record in NET biology and translational research and with proven experience in human explant and animal in vivo models for RA, SLE, Interstitial Lung Disease (ILD) and IPF, vasculitis and Alzheimer’s disease.
If you are interested in discussing how we may work together, please contact us through this page.